Cargando…
A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases
BACKGROUND: Several bone-seeking radionuclides have been developed for palliation of metastatic bone pain since 1956, however, so far radium-223 dichloride is the first and only Food and Drug Administration (FDA) approved targeted alpha therapy for metastatic castration-resistant prostate cancer (mC...
Autores principales: | Myint, Zin W., El Khouli, Riham, Lemieux, Bryan, Yan, Donglin, St. Clair, William H., Liu, Xiaoqi, Kunos, Charles A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013149/ https://www.ncbi.nlm.nih.gov/pubmed/35428207 http://dx.doi.org/10.1186/s12885-022-09496-2 |
Ejemplares similares
-
Radiopharmaceutical Validation for Clinical Use
por: Kunos, Charles A., et al.
Publicado: (2021) -
Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study
por: Zhou, Tie, et al.
Publicado: (2020) -
Bone Fracture Incidence After Androgen Deprivation Therapy-Investigational Agents: Results From Cancer Therapy Evaluation Program-Sponsored Early Phase Clinical Trials 2006–2013
por: Myint, Zin W., et al.
Publicado: (2020) -
A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
por: Myint, Zin W., et al.
Publicado: (2021) -
Anisotropy of the Radiation Field Following Canine Sn-117m Treatment
por: Arno, Matthew G., et al.
Publicado: (2021)